Equity Profile

CNTA

Centessa Pharmaceuticals plc

Health CareBiotechnology$6.2B

May5Tue

Post-Earnings Recap

ReportedQ1-2026After Close4:04 PM EDT

Centessa Pharmaceuticals Misses on EPS, Stock Down 0.08%

Metric	Actual	Expected	Surprise
EPS	$-0.52	N/A	-36.84%
Revenue	—	N/A	—

management commentary, guidance changes, and full analysis available with Pro.

Centessa Pharmaceuticals Misses on EPS, Stock Down 0.08%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$-0.52	N/A	-36.84%
Revenue	—	N/A	—

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based solely on numerical results.

What It Means

Centessa Pharmaceuticals reported a larger-than-expected loss per share, which may raise concerns among investors about the company's financial health. The stock reacted slightly down by 0.08%, indicating a muted response to the earnings report. Without additional context from management commentary or guidance, investors are left to assess the implications based solely on the reported EPS.

Company Snapshot

Centessa Pharmaceuticals plc (CNTA) is a biotechnology company focused on developing innovative therapies for serious diseases. With a market cap of $6 billion, it operates in the health care sector, aiming to address unmet medical needs through its diverse pipeline of drug candidates.

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will help gauge the company's financial health this quarter.

N/A

Revenue

Revenue figures will provide insight into the company's market performance and the success of its product pipeline.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-51.59%

Avg Stock Reaction

+6.48%

Last Quarter Recap

In Q4 2025, Centessa reported an EPS of -$1.46, significantly missing estimates, which led to a 44% increase in stock the following day. This volatility reflects investor sentiment and potential for recovery despite the disappointing earnings.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations for Centessa's upcoming earnings are mixed, with uncertainty surrounding its ability to meet or exceed prior performance. Investors are keenly watching for any signs of improvement in its drug pipeline.

Bull Case

If Centessa can demonstrate progress in its clinical trials or provide positive updates on its drug candidates, it could lead to a strong rebound in investor confidence and stock price.

Bear Case

Conversely, if the company reports further losses or delays in its pipeline, it may lead to a decline in stock value as investors reassess the company's future prospects.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific advancements can Centessa report regarding its drug candidates?

Updates on drug development are crucial for investor confidence and can significantly impact stock performance.

Will the company provide any guidance on future revenue expectations?

Guidance on revenue can help investors gauge the company's growth trajectory and market potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Centessa's drug pipeline to yield positive results, despite recent setbacks.

Supporting Evidence

The options market is pricing a smaller move than historical averages, suggesting a lack of confidence in a significant downturn.

Centessa's recent stock price movements indicate that investors may be overly pessimistic about its future prospects.

Key Risk

If Centessa reports any positive developments in its drug pipeline, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate revolves around Centessa's ability to execute on its drug development plans and the financial implications of its current performance.

Bull Confirmed If

A positive update on clinical trial results or a new partnership would signal strong potential for growth.

Bear Confirmed If

Further delays in the drug pipeline or larger-than-expected losses would confirm bearish sentiment.

Pre-Earnings Positioning

Options Market

Implied Move

±4.03%

Historical Avg

±8.35%

Pricing cheap

The options market is pricing in a modest move of around 4%, indicating uncertainty about the upcoming earnings report.

Options are pricing a 4.03% move, while the stock has averaged an 8.35% move historically, suggesting a potentially undervalued setup.

Detail

ATM IV

0.1%

30d HV

108.9%

Calls (88K)P/C Ratio: 6.66Puts (26K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Centessa beats expectations, history suggests a potential average move of +0.49%, confirming a positive outlook for the company.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await more clarity.

Miss

Should the company miss expectations, history suggests an average move of +10.37%, indicating a possible sell-off as investors react to the news.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of clinical trials for key drug candidates.
2Any new partnerships or collaborations that could enhance the pipeline.
3Management's outlook on revenue expectations for the upcoming quarters.
4Insights into cost management strategies and their impact on future profitability.
5Responses to analyst questions regarding the competitive landscape in biotechnology.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

GRABReported

Grab Holdings Limited

RecapView

May4

GBDCReported

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will help gauge the company's financial health this quarter.

N/A

Revenue

Revenue figures will provide insight into the company's market performance and the success of its product pipeline.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-51.59%

Avg Stock Reaction

+6.48%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Centessa can demonstrate progress in its clinical trials or provide positive updates on its drug candidates, it could lead to a strong rebound in investor confidence and stock price.

Bear Case

Conversely, if the company reports further losses or delays in its pipeline, it may lead to a decline in stock value as investors reassess the company's future prospects.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific advancements can Centessa report regarding its drug candidates?

Updates on drug development are crucial for investor confidence and can significantly impact stock performance.

Will the company provide any guidance on future revenue expectations?

Guidance on revenue can help investors gauge the company's growth trajectory and market potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Centessa's drug pipeline to yield positive results, despite recent setbacks.

Supporting Evidence

The options market is pricing a smaller move than historical averages, suggesting a lack of confidence in a significant downturn.

Centessa's recent stock price movements indicate that investors may be overly pessimistic about its future prospects.

Key Risk

If Centessa reports any positive developments in its drug pipeline, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate revolves around Centessa's ability to execute on its drug development plans and the financial implications of its current performance.

Bull Confirmed If

A positive update on clinical trial results or a new partnership would signal strong potential for growth.

Bear Confirmed If

Further delays in the drug pipeline or larger-than-expected losses would confirm bearish sentiment.

Pre-Earnings Positioning

Options Market

Implied Move

±4.03%

Historical Avg

±8.35%

Pricing cheap

The options market is pricing in a modest move of around 4%, indicating uncertainty about the upcoming earnings report.

Options are pricing a 4.03% move, while the stock has averaged an 8.35% move historically, suggesting a potentially undervalued setup.

Detail

ATM IV

0.1%

30d HV

108.9%

Calls (88K)P/C Ratio: 6.66Puts (26K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Centessa beats expectations, history suggests a potential average move of +0.49%, confirming a positive outlook for the company.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await more clarity.

Miss

Should the company miss expectations, history suggests an average move of +10.37%, indicating a possible sell-off as investors react to the news.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress of clinical trials for key drug candidates.
2Any new partnerships or collaborations that could enhance the pipeline.
3Management's outlook on revenue expectations for the upcoming quarters.
4Insights into cost management strategies and their impact on future profitability.
5Responses to analyst questions regarding the competitive landscape in biotechnology.